Robert E. Hawkins
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.1%
- Renal cell carcinoma treatment
Papers in
- Oncology 70
- CAR-T cell therapy research 48
- Cancer Immunotherapy and Biomarkers 15
- Immunology 53
- Immunotherapy and Immune Responses 44
- T-cell and B-cell Immunology 11
- Co-authors
- Greg P. Winter (9 shared papers)David Edward Gilham (49 shared papers)Andrew D. Griffiths (1 shared paper)Hennie R. Hoogenboom (1 shared paper)Stephen J. Russell (9 shared papers)Cezary A. Szczylik (6 shared papers)Cora Nanette Sternberg (6 shared papers)John D. Wagstaff (5 shared papers)
- Journals
- British Journal of Cancer (13 papers)Cancer Immunology Immunotherapy (13 papers)Journal of Immunotherapy (11 papers)Annals of Oncology (10 papers)European Journal of Cancer (8 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Robert E. Hawkins
204 papers receiving 23k citations
Robert E. Hawkins's Hit Papers
Peers
Comparison fields: 5 of 140
- Oncology 6.9k
- Pulmonary and Respiratory Medicine 9.3k
- Immunology 2.4k
- Radiology, Nuclear Medicine and Imaging 2.2k
- Cancer Research 544
Countries citing papers authored by Robert E. Hawkins
This map shows the geographic impact of Robert E. Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Hawkins more than expected).
Fields of papers citing papers by Robert E. Hawkins
This network shows the impact of papers produced by Robert E. Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Hawkins. The network helps show where Robert E. Hawkins may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert E. Hawkins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 206 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3686 |
| 2 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2674 |
| 3 | Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Hit paper breakdown → | 2010 | 2072 |
| 4 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2013 | 1585 |
| 5 | Making Antibodies by Phage Display Technology Hit paper breakdown → | 1994 | 1308 |
| 6 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 826 |
| 7 | Cancer classification using the Immunoscore: a worldwide task force Hit paper breakdown → | 2012 | 694 |
| 8 | Selection of phage antibodies by binding affinity Hit paper breakdown → | 1992 | 437 |
| 9 | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update Hit paper breakdown → | 2013 | 379 |
| 10 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Hit paper breakdown → | 2016 | 361 |
| 11 | 2017 | 339 | |
| 12 | Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study Hit paper breakdown → | 2014 | 330 |
| 13 | 2005 | 280 | |
| 14 | 2005 | 277 | |
| 15 | 2010 | 222 | |
| 16 | 2002 | 215 | |
| 17 | 2010 | 215 | |
| 18 | 1996 | 202 | |
| 19 | 2007 | 178 | |
| 20 | 1993 | 177 |
About Robert E. Hawkins
Robert E. Hawkins is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 206 papers that have together received 23.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (53 papers), CAR-T cell therapy research (48 papers), Immunotherapy and Immune Responses (44 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Cancer Immunotherapy and Biomarkers (15 papers), Virus-based gene therapy research (12 papers), T-cell and B-cell Immunology (11 papers) and Gastric Cancer Management and Outcomes (5 papers). The work is most often cited by research in Oncology (6.9k citations), Pulmonary and Respiratory Medicine (9.3k citations), Immunology (2.4k citations), Radiology, Nuclear Medicine and Imaging (2.2k citations) and Cancer Research (544 citations). Robert E. Hawkins has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Greg P. Winter, David Edward Gilham, Andrew D. Griffiths, Hennie R. Hoogenboom, Stephen J. Russell, Cezary A. Szczylik, Cora Nanette Sternberg, John D. Wagstaff, Lauren A. McCann and Ian D. Davis. Their work appears in journals such as British Journal of Cancer, Cancer Immunology Immunotherapy, Journal of Immunotherapy, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.